Skip to content
Screener

Allogene Therapeutics ALLO Business Segments — Payroll

Similar metrics at other companies

Nutex Health Inc. logo
NUTXHospital division revenue — Payroll
$42.31M+17.8%
Tilly's logo
TLYSReportable Segment — Store payroll
$20.42M+2.2%
Barnes & Noble Education logo
BNEDReportable Segment — Payroll expense
$51.61M-5.0%
MSC Industrial Direct Co. logo
MSMReportable Segment — Payroll and payroll-related costs
$173.84M-0.8%
CuriosityStream logo
CURIReportable Segment — Payroll and related
$2.89M+9.8%
Butterfly Network logo
BFLYReportable segment — Payroll operating expenses
$14.79M+14.1%

Other financials

Income statement

See full
Revenue-
Operating income-$46.1M+29.3%
Net income-$42.6M+28.7%
EPS (diluted)-$0.18+35.7%

Balance sheet

See full
Cash & equivalents$40.6M-23.0%
Total debt$81.1M-8.9%
Total equity$278.9M-27.6%
Total assets$396.0M-22.1%

Cash flow

See full
Operating cash flow-$12.9M+75.6%
CapEx$9.0K-90.9%
Free cash flow-$12.9M+75.6%

Valuation

See full
Market cap$693.76M+205%
Enterprise value$734.21M+192%

Profitability

See full
Operating margin-1,241,813.6%-2,018,140pp
Net margin-1,170,863.6%-2,007,890pp
FCF margin-913,609.1%-1,474,890pp

Returns & leverage

See full
Return on equity-52.3%-5.7pp
Debt / equity0.3×+0.1×
Current ratio9.6×-0.1×

Where this comes from

Reported directly by Allogene Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:LaborAndRelatedExpense.

The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:05 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-034585
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Significant operating expenses:
Cema-cel$7,669$6,222
All other development costs1,99910,390
Payroll14,44419,601
Facilities & IT-related spend6,4187,319
Supporting external spend4,3725,846
Other operating expenses11,19015,813
Total operating expenses46,09265,191

Item 1. Financial Statements - Unaudited

FAQ

What is Allogene Therapeutics's business segments — payroll?
Allogene Therapeutics (ALLO) reported business segments — payroll of $14.44M in Q1 2026.
How has Allogene Therapeutics's business segments — payroll changed year-over-year?
Allogene Therapeutics's business segments — payroll decreased by 26.3% year-over-year, from $19.6M to $14.44M.
What is the long-term trend for Allogene Therapeutics's business segments — payroll?
Over 2 years (2023 to 2025), Allogene Therapeutics's business segments — payroll has grown at a -15.4% compound annual growth rate (CAGR), from $87.85M to $62.91M.
What does business segments — payroll mean?
This metric measures the total compensation and benefits costs for personnel directly associated with the reportable segment's operations. It serves as a proxy for the human capital investment required to sustain clinical development and operational activities. Changes in this figure often indicate shifts in headcount or organizational scaling.

Ask your AI about Allogene Therapeutics's business segments — payroll.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude